Mexico pushing for their own experimental homegrown swine flu vaccine... Oct 23, 2009
Dr. Rahul Singhvi, president and CEO of Novavax Inc., the company manufacturing the new vaccine, said: "We absolutely want to help Mexico in getting more vaccine. We want to save lives in Mexico.". U.s experts praised the idea. (The Drudge Report)
Novavax steps up H1N1 vaccine production Oct 22, 2009
The Rockville-based company says it has entered into a strategic collaboration with It will combine Novavax's virus-like particle vaccine technology, which produces vaccines much faster than traditional methods, with Xcellerex's manufacturing methods that use disposable production and automation techniques that it says simplifies vaccine manufacturing ... Novavax (NASDAQ: NVAX) says the partnership with Xcellerex will also help speed commercial production for its seasonal influenza vaccine,... (Baltimore Business Journal, MD)
Novavax, partner to test H1N1 vaccine Oct 21, 2009
Through early next year, the companies will be testing Novavax s vaccine technology, which uses lab-created virus-like particles rather than the entire live virus strain, to make up a vaccine against seasonal and pandemic flu, including the swine flu. Novavax, which has said its method results in much faster production of flu vaccines than the traditional methods of growing virus strains in chicken eggs, said successful tests in Mexico could lead that government to approve the sale of an H1N1... (Washington Business Journal, DC)
Virus-like particles may fast-track vaccines Oct 1, 2009
Virus-like particles (VLPs), mere shells of actual viruses, can be used to create vaccines in weeks instead of months, according to Novavax Inc. of Rockville, Md ... "The outside of the virus-like particles looks like a virus," said Rahul Singhvi, the president and CEO of Novavax, "but inside there is no genetic material." ... Novavax can produce sooner than traditional makers, because they don't have to wait for the CDC to create the seed virus. (MSNBC -- Technology)
Cel-Sci , Novavax to raise $30M Sep 22, 2009
Rockville-based Novavax has submitted a regulatory filing that registers up to 3. 4 million of its shares for a later stock sale. (Washington Business Journal, DC)
Investors look for stocks that could gain from swine flu Sep 22, 2009
Other smaller firms working on H1N1 vaccines include Novavax and Vical , Kolbert says. If those vaccines pan out, they could be more meaningful than Tamiflu is to Gilead at 5% of revenue, Schwartz says. (USA Today -- Money)
VLP could make flu vaccine faster, better Sep 20, 2009
Ralph Tripp, of UGA and associate director of the joint influenza center of excellence, said his lab is testing a VLP vaccine, created by Novavax, in pigs with the new virus. "You could cut out several months, get it down to at least on the order of as little as two months," Dr. Compans said. (The Augusta Chronicle)
Building a Better Flu Vaccine--And Giving Chickens a Rest Sep 3, 2009
BREAKING NEWS: Biotech company Novavax, Inc., says the most recent trial testing its seasonal flu vaccine--made using viruslike particles rather than fertilized chicken eggs--was encouraging in that the vaccine significantly boosted antibody counts in the majority of participants ... Novavax says it can develop a prototype vaccine without the aid of a virus reference strain ... Novavax says that during Phase IIa of seasonal flu vaccine testing, which began in May, it was able in the majority of... (Scientific American)
Novavax reports positive test results for swine flu vaccine Sep 2, 2009
Novavax reports good results from swine flu vaccine - Washington Business Journal ... Novavax reports good results from swine flu vaccine ... Novavax (NASDAQ: NVAX) said volunteers who experienced high immunity responses to its VLP vaccine ranged from 81 percent to 86 percent of its group for one seasonal strain called H3N2, from 57 percent to 66 percent for the H1N1 strain and from 62 percent to 67 percent for a third seasonal flu strain. (Washington Business Journal, DC)
H1N1 vaccine ready, India yet to book doses Aug 29, 2009
(Cadila Pharma is also developing a vaccine in collaboration with US company Novavax). Serum Institute executive director SS Jadhav told TOI, No talks have been held with procurement agencies regarding their plans of stockpiling the vaccine, including the quantity required and target group of population. (India Times, India)
Tobacco Might Produce Vaccine for Stomach Virus Aug 20, 2009
Vaccine maker Novavax Inc. said on Tuesday it made its H1N1 vaccine, which uses virus-like particles grown in caterpillar cells, in four weeks. (Editing by Todd Eastham). (MEDLINEplus)
Novavax says vaccine works in ferrets Aug 19, 2009
The study, conducted with scientists from both Novavax and the Centers for Disease Control and Prevention, showed the virus successfully protected ferrets, even at low doses ... Novavax made its virus-like particle vaccine, one that mimics a virus but cannot replicate, in just 11 weeks, significantly faster than traditional vaccine production ... Novavax stock (NASDAQ: NVAX) was up 45 cents to $4. (Washington Business Journal, DC)
Indian pharmaceutical firm to apply for trials of A/H1N1 flu vaccine Aug 18, 2009
Cadila will file an application with the Drug Controller General of India, seeking permission for clinical trials of an A/H1N1 flu vaccine that the company is preparing in collaboration with Novavax Inc.. "Maybe tomorrow, we will file an application for clinical trials. God willing by January, we should be able to give the product to the market. Cadila should be the first company in India to have both clinical trials and vaccine for swine flu," Cadila Chairman Indravadan Modi told Xinhua on the... (Xinhuanet, China)
H1N1 vaccine: Cadila for clinical trials Aug 12, 2009
Cadila Pharmaceutical Ltd (CPL) had set up a joint venture 'CPL Biologicals Pvt Ltd' with the US-based vaccine maker Novavax for manufacturing and developing a host of vaccines, including for swine flu, in India ... "Novavax has already received permission for clinical trials from the US Federal Drug Administration and if we get it soon, we can simultaneously start the trials," he added ... In the joint venture Cadila has 80 per cent stake and the remaining 20 per cent is held by Novavax. (India Times, India)
Cadila Pharma plans swine flu vaccine by November Aug 11, 2009
CPL had set up a joint venture (JV) on July 9 with the US-based vaccine maker Novavax for manufacturing of vaccines, including one for swine flu ... Novavax has already received permission for pre-clinical trials from US Federal Drug Administration, IA Modi, chairman and managing director, CPL, told TOI. ... CPL has 80% equity and Novavax 20% in the JV. It may be pointed out that Cadila Pharma also holds 5. (India Times, India -- Community News)
Novavax stock rallies on swine flu breakthrough Aug 6, 2009
Novavax rallies on Swine flu breakthrough - Washington Business Journal ... Novavax rallies on Swine flu breakthrough ... Novavax says it created the vaccine candidate just 11 weeks after getting the gene sequence for the N1H1 strain from the U.S. Centers for Disease Control. (Washington Business Journal, DC)
Novavax repays last of $22M debt Jul 16, 2009
Instead, Novavax said today it has paid off the last $5 million of its convertible debt notes ... For this last repayment, Novavax (NASDAQ: NVAX) said it paid $2 ... In April, Novavax paid off the first $17 million chunk with nearly $12 million in cash and the rest in stock. (Washington Business Journal, DC)
Novavax stock soars on license deal with European company Jul 1, 2009
Novavax stock soars on license deal - Washington Business Journal ... Novavax stock soars on license deal ... Novavax has been in the second phase of human clinical testing for the technology on roughly 300 patients. (Washington Business Journal, DC)
The following is an investment opinion release issued by Pennystockchaser.com Jun 22, 2009
Novavax Inc. NVAX, sector: Medical, industry: Biotechnology. Uranium Hunter Corp. URNH, sector: Mining, industry: Exploration. (PR Newswire)
Tips from the journals of the American Society for Microbiology Jun 20, 2009
The researchers from the National Center for Immunization and Respiratory Diseases, Collaborating Centers for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; and Novavax, Inc., Rockville, Maryland report their findings in the June 2009 issue of the Journal of Virology. More than 220,000 hospitalizations and approximately 36,000 deaths are attributed to influenza A viruses each year. (EurekAlert!)
OffTheWallStocks featuring on its newsletter: WIND, OMEX, FR, AGEN, HEB, NVAX Jun 5, 2009
Today's focused alerts include: Wind River Systems (Nasdaq: ), Odyssey Marine Exploration (Nasdaq: ), First Industrial Realty Trust (NYSE: ), Antigenics Inc Del (Nasdaq: ), Hemispherx Biopharma Inc (AMEX: ), Novavax Inc (Nasdaq: ). OffTheWallStocks. (PR Newswire)
GEN reports on efforts to quickly develop swine flu vaccine Jun 3, 2009
Novavax plans to create a virus-like particle-based (VLP) vaccine against the H1N1 strain, which obviates the need for a live virus seed for manufacturing. The VLPs contain the proteins that make the virus' outer shell and the surface proteins, without the RNA required for replication. (EurekAlert!)
Researchers Look for Ways to Deliver a One-Two Punch to Flu Viruses Jun 3, 2009
Biotech firm Novavax, Inc., in Rockville, Md. has begun developing a prototype swine flu vaccine using information the CDC posted to the Global Initiative on Sharing Avian Influenza Data (GISAID) database, launched in 2006 by a number of government organizations, science institutes and universities worldwide (including the World Health Organization, CDC, and the Max Planck Institute for Informatics) to encourage data-sharing in response to the global spread of the. (Scientific American)
1-Star Stocks Poised to Plunge: Novavax? May 9, 2009
1-Star Stocks Poised to Plunge: Novavax ... 1-Star Stocks Poised to Plunge: Novavax ... Based on the aggregated intelligence of 130,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, vaccine maker Novavax (Nasdaq: NVAX) has received the dreaded one-star ranking. (MSNBC -- Business)
Novavax reports wider losses May 9, 2009
Novavax says it spent $7 ... Novavax began development of a vaccine for the N1H1 influenza virus and says it is in contact with government and health authorities about its progress ... Novavax s technology for producing vaccines can cut the manufacturing time in half. (Washington Business Journal, DC)
More of this story May 4, 2009
The Truth wrote on May 3, 2009 11:33 AM:" I hope to shed some light on this subject, so maybe people can understand what is Really Going on with the so called "Swine Flu". This Is nothing more than a psych op, Yes The H1N1 Flu Virus is real, But its not Pandemic strength. First off N1H1 did not come from Swine, It was Gene Spliced at NOVAVAX in Maryland, Publicly traded as NVAX. There Share was at a all time low on March 5th t 0.56 cents a share, on April 28th It Spiked at $3.18 a Share. Now Do... (Westerly Sun, RI)
Ever-changing virus challenges drugmakers May 3, 2009
Companies such as Rockville-based Novavax are trying to cut production times even further. Novavax also grows flu vaccines in cells, but instead of using the actual virus, the company uses genetic information from the virus to create a decoy ... Rahul Singhvi, Novavax's chief executive, said his company can make flu vaccines in up to three months and is working on a swine flu vaccine. (MSNBC -- Health)
Region's biotechs step up efforts to fight swine flu May 2, 2009
Novavax, a Rockville biotech that received an 80 percent boost in its stock price Monday as swine flu first swept across headlines, said it could produce a vaccine in as little as 10 to 12 weeks using an emerging vaccine production technology that uses virus-like particles, rather than the entire virus strain ... We can produce vaccines faster and make them available for first responders before bigger capacity comes online, said Rahul Singhvi, CEO of Novavax, during an analyst call. (Baltimore Business Journal, MD)
Biotechs work to combat swine flu May 1, 2009
Novavax, a Rockville biotech that received an 80 percent boost in its stock price Monday as swine flu first swept across headlines, said it could produce a vaccine in as little as 10 to 12 weeks using an emerging vaccine production technology that uses virus-like particles, rather than the entire virus strain ... We can produce vaccines faster and make them available for first responders before bigger capacity comes online, said Rahul Singhvi, president and CEO of Novavax, during an analyst... (Washington Business Journal, DC)
Local Company Says It Can Cut Flu Vaccine Production Time In Half Apr 30, 2009
Novavax's seasonal flu vaccine is still in clinical trials ... Novavax is working on something completely different ... In a small lab in Rockville's biotech corridor, Novavax is growing gallons of the virus like particles. (W-USA News, DC)
How Fast Could a Swine Flu Vaccine Be Produced? Apr 30, 2009
At the biotech company Novavax, researchers are testing the use of virus-like particles (VLP), instead of the virus itself, to stimulate a flu immune response ... "We have made vaccines against multiple flu strains and tested them in humans and gotten relevant and robust immune responses, which checks off the major boxes that the technology works against flu," says Rahul Singhvi, president and CEO of Novavax ... Novavax's strategy involves isolating three proteins from the virus that flag the... (Time.com)
Region Prepares for Potential Swine Flu Outbreak Apr 29, 2009
Sources say locally based Novavax is working on a vaccine that could be completed in as soon as 10 weeks. ABC 7 Talkback. (ABC 7 News, DC)
» Swine flu fears a boon? Apr 29, 2009
-based biotech company Novavax Inc. could see a benefit from the outbreak, as its technology is one of the fastest methods for creating a vaccine. "If the infection escalates and a government body decides to stockpile vaccine, we believe that Novavax is well positioned to capitalize on this opportunity with its recombinant vaccine technology," Piros said in a note to investors ... Novavax shares nearly doubled in price to $2. (Northwest Indiana Times)
Flu's bad news but shot in the arm for biotech Apr 28, 2009
Meanwhile, Novavax Inc., of Rockville, Md ... The Bay Area connection: As part of its Pandemic and Bio Defense Fund, Menlo Park's Kleiner Perkins Caufield invested $20 million in Novavax and $30 million in BioCryst. (San Francisco Chronicle -- Business)
Swine flu fear lifts Novavax stock Apr 28, 2009
Shares of Rockville-based Novavax (NASDAQ: NVAX) rose as much as $2 ... By the closing bell, that frenzy subsided a bit, and Novavax closed up 80 percent to $2 ... Last summer, Novavax announced that its experimental vaccine against one strain of avian influenza produced a strong immune response in humans. (Washington Business Journal, DC)
Glaxo, Novavax, other drug stocks leap due to swine flu Apr 28, 2009
Novavax, a Maryland-based company that in 2005 turned its attention to flu vaccines, saw its shares leap 80% Monday. Novavax is testing cell-based technologies to enable it to produce a flu vaccine in as little as three months, says equity analyst Elemer Piros at Rodman & Renshaw. (USA Today -- News)
Novavax to get capital infusion Apr 1, 2009
Rockville-based Novavax, which is developing vaccines for influenza and HIV, reported a net loss of $11 million, or 15 cents per share, for the fourth quarter of 2008 compared to a net loss of $9 ... On Tuesday the company also announced a joint venture between Ltd. and Novavax in India, which will be owned 80 percent by Cadila and 20 percent by Novavax, pending approval of the India Foreign Investment Promotion Board ... The partners will develop and commercialize Novavax s seasonal influenza... (Washington Business Journal, DC)
Biotechs go without CFOs in midst of economic recession Mar 13, 2009
At Rockville s Novavax, which is trying to raise $25 million partly to help pay off pending debt, CFO Len Stigliano left in January to be closer to his Pennsylvania home ... We have a very strong financial team, said Novavax s chief executive officer, Rahul Singhvi. (Washington Business Journal, DC)
Novavax taps interim accounting chief Feb 10, 2009
Novavax taps Evdoxia Kopsidas as interim accounting chief - Washington Business Journal ... Novavax taps Evdoxia Kopsidas as interim accounting chief ... A former controller for and , Kopsidas steps in for former Chief Financial Officer Len Stigliano, who had joined Novavax in April 2007 as an interim CFO himself. (Washington Business Journal, DC)
